Background
Chronic kidney disease is characterised by low estimated glomerular
filtration rate (eGFR) and high albuminuria, and is associated with adverse
outcomes. Whether these risks are modified by diabetes is unknown.
Methods
We did a meta-analysis of studies selected according to Chronic
Kidney Disease Prognosis Consortium criteria. Data transfer and analyses
were done between March, 2011, and June, 2012. We used Cox proportional
hazards models to estimate the hazard ratios (HR) of mortality and end-stage
renal disease (ESRD) associated with eGFR and albuminuria in individuals
with and without diabetes.
Findings
We analysed data for 1 024 977 participants (128 505 with diabetes)
from 30 general population and high-risk cardiovascular cohorts and 13
chronic kidney disease cohorts. In the combined general population and
high-risk cohorts with data for all-cause mortality, 75 306 deaths occurred
during a mean follow-up of 8·5 years (SD 5·0). In the 23
studies with data for cardiovascular mortality, 21 237 deaths occurred from
cardiovascular disease during a mean follow-up of 9·2 years (SD
4·9). In the general and high-risk cohorts, mortality risks were
1·2–1·9 times higher for participants with diabetes
than for those without diabetes across the ranges of eGFR and
albumin-to-creatinine ratio (ACR). With fixed eGFR and ACR reference points
in the diabetes and no diabetes groups, HR of mortality outcomes according
to lower eGFR and higher ACR were much the same in participants with and
without diabetes (eg, for all-cause mortality at eGFR 45 mL/min per
1·73 m2 [νs 95 mL/min
per 1·73 m2], HR 1·35; 95% CI
1·18–1·55; νs 1·33;
1·19–1·48 and at ACR 30 mg/g
[νs 5 mg/g], 1·50;
1·35–1·65 νs 1·52;
1·38–1·67). The overall interactions were not
significant. We identified much the same findings for ESRD in the chronic
kidney disease cohorts.
Interpretation
Despite higher risks for mortality and ESRD in diabetes, the relative
risks of these outcomes by eGFR and ACR are much the same irrespective of
the presence or absence of diabetes, emphasising the importance of kidney
disease as a predictor of clinical outcomes.
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
A panel of internists and nephrologists developed this practical approach for the Kidney Disease Outcomes Quality Initiative to guide assessment and care of chronic kidney disease (CKD) by primary care clinicians. Chronic kidney disease is defined as a glomerular filtration rate (GFR) <60 mL/min/1.73 m(2) and/or markers of kidney damage for at least 3 months. In clinical practice the most common tests for CKD include GFR estimated from the serum creatinine concentration (eGFR) and albuminuria from the urinary albumin-to-creatinine ratio. Assessment of eGFR and albuminuria should be performed for persons with diabetes and/or hypertension but is not recommended for the general population. Management of CKD includes reducing the patient's risk of CKD progression and risk of associated complications, such as acute kidney injury and cardiovascular disease, anemia, and metabolic acidosis, as well as mineral and bone disorder. Prevention of CKD progression requires blood pressure <140/90 mm Hg, use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for patients with albuminuria and hypertension, hemoglobin A1c ≤7% for patients with diabetes, and correction of CKD-associated metabolic acidosis. To reduce patient safety hazards from medications, the level of eGFR should be considered when prescribing, and nephrotoxins should be avoided, such as nonsteroidal anti-inflammatory drugs. The main reasons to refer to nephrology specialists are eGFR <30 mL/min/1.73 m(2), severe albuminuria, and acute kidney injury. The ultimate goal of CKD management is to prevent disease progression, minimize complications, and promote quality of life.
An arteriovenous fistula (AVF) is the optimal vascular access for hemodialysis (HD), because it is associated with prolonged survival, fewer infections, lower hospitalization rates, and reduced costs. The AVF First breakthrough initiative (FFBI) has made dramatic progress, effectively promoting the increase in the national AVF prevalence since the program's inception from 32% in May 2003 to nearly 60% in 2011. Central venous catheter (CVC) use has stabilized and recently decreased slightly for prevalent patients (treated more than 90 days), while CVC usage in the first 90 days remains unacceptably high at nearly 80%. This high prevalence of CVC utilization suggests important specific improvement goals for FFBI. In addition to the current 66% AVF goal, the initiative should include specific CVC usage target(s), based on the KDOQI goal of less than 10% in patients undergoing HD for more than 90 days, and a substantially improved initial target from the current CVC proportion. These specific CVC targets would be disseminated through the ESRD networks to individual dialysis facilities, further emphasizing CVC avoidance in the transition from advanced CKD to chronic kidney failure, while continuing to decrease CVC by prompt conversion of CVC-based hemodialysis patients to permanent vascular access, utilizing an AVF whenever feasible.
This US, multicenter, observational study assessed the CKD prevalence in adult patients with type-2 diabetes mellitus (T2DM) and characterized the proportion of detected and undiagnosed CKD in the primary care setting using the following: a clinician survey; a patient physical exam and medical history; a single blood draw for estimated glomerular filtration rate (eGFR) and glycosolated hemoglobin (HbA1c); urine dipstick for protein; urine albumin-creatinine ratio (ACR); two patient quality of life questionnaires; and a 15-month medical record review. The study consisted of 9339 adults with T2DM and 466 investigator sites. Of the 9339 enrolled, 9307 had complete data collection for analysis. The 15-month retrospective review showed urine protein, urine ACR, and eGFR testing were not performed in 51.4%, 52.9% and 15.2% of individuals, respectively. Of the 9307 patients, 5036 (54.1%) had Stage 1–5 CKD based on eGFR and albuminuria; however, only 607 (12.1%) of those patients were identified as having CKD by their clinicians. Clinicians were more successful in diagnosing patients with Stage 3–5 CKD than Stages 1 and 2. There were no differences in clinicians’ likelihood of identification of CKD based on practice setting, number of years in practice, or self-reported patients seen per week. Awareness or patient self-reported CKD was 81.1% with practitioner detection versus 2.6% in the absence of diagnosis. Primary care of T2DM demonstrates recommended urine CKD testing is underutilized, and CKD is significantly under-diagnosed. This is the first study to show CKD detection is associated with awareness.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.